PHIO — Phio Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $2.83m
- -$1.87m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 0.17 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.75 | ||
| Price to Tang. Book | 0.75 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -233.18% | ||
| Return on Equity | -126.86% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.02 | n/a | n/a | n/a | n/a | n/a | 75 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
Directors
- Robert Bitterman NEC (70)
- Gerrit Dispersyn PRE (46)
- Geert Cauwenbergh IND (67)
- H. Paul Dorman IND (84)
- Robert Ferrara IND (70)
- Jonathan Freeman IND (53)
- Curtis Lockshin IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- September 8th, 2011
- Public Since
- May 10th, 2012
- No. of Shareholders
- 19
- No. of Employees
- 8
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 860,721
- Address
- 11 APEX DRIVE, SUITE 300A, PMB 2006, MARLBOROUGH, 01752
- Web
- https://phiopharma.com/
- Phone
- +1 5087673861
- Auditors
- BDO USA, LLP
Upcoming Events for PHIO
Similar to PHIO
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Phio Pharmaceuticals share price?
As of Today at 23:06 UTC, shares in Phio Pharmaceuticals are trading at $3.29. This share price information is delayed by 15 minutes.
How has the Phio Pharmaceuticals share price performed this year?
Shares in Phio Pharmaceuticals last closed at $3.29 and the price had moved by -79.05% over the past 365 days. In terms of relative price strength the Phio Pharmaceuticals share price has underperformed the S&P500 Index by -83.43% over the past year.
What are the analyst and broker recommendations for Phio Pharmaceuticals?
The overall consensus recommendation for Phio Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Phio Pharmaceuticals dividend yield?
Phio Pharmaceuticals does not currently pay a dividend.
Does Phio Pharmaceuticals pay a dividend?
Phio Pharmaceuticals does not currently pay a dividend.
When does Phio Pharmaceuticals next pay dividends?
Phio Pharmaceuticals does not currently pay a dividend.
How do I buy Phio Pharmaceuticals shares?
To buy shares in Phio Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Phio Pharmaceuticals?
As of the previous close price of $3.29, shares in Phio Pharmaceuticals had a market capitalisation of $2.83m.
Where are Phio Pharmaceuticals shares listed?
Here are the trading details for Phio Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PHIO
What kind of share is Phio Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Phio Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Phio Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Phio Pharmaceuticals is $36.00. That is 994.22% above the last closing price of $3.29.
Analysts covering Phio Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$16.38 for the next financial year.
Find out moreWhat is the trend in the Phio Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Phio Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -64.74%.
As of the last closing price of $3.29, shares in Phio Pharmaceuticals were trading -45.58% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Phio Pharmaceuticals PE Ratio?
The Phio Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 0.17. The shares last closed at $3.29.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Phio Pharmaceuticals?
Phio Pharmaceuticals' management team is headed by:
- Robert Bitterman - NEC
- Gerrit Dispersyn - PRE
- Geert Cauwenbergh - IND
- H. Paul Dorman - IND
- Robert Ferrara - IND
- Jonathan Freeman - IND
- Curtis Lockshin - IND